Articles from Darwin Biotechnology

Darwin Biotech (“Darwin”), a clinical-stage company developing treatments for neurological diseases, today announced that data from its randomized, double-blind, placebo-controlled Phase 1 study of ALT001 in amyotrophic lateral sclerosis (ALS), including 12-week results from an ongoing open-label extension (OLE), were presented in a poster at the 2026 Network of Excellence for ALS (NEALS) Annual Meeting, taking place October 27-30 in Clearwater, Florida.